Resources

See below for important resources for your practice and patients with COPD.

Prescribing Ohtuvayre

Ohtuvayre Prescribing Guide

Provides helpful information about prescribing Ohtuvayre and the support available to you and your patients through Verona Pathway Plus™.

Ohtuvayre Prescription and Patient Enrollment & Consent Form

Use this form when prescribing Ohtuvayre for your patients.

EMR Prescribing Guide

A resource that highlights how to prescribe Ohtuvayre through your EMR.

Verona Pathway Plus Portal

An online portal that helps track patient progress through treatment.

Ohtuvayre Veterans Affairs (VA) Prescription Form

Use this form when prescribing Ohtuvayre for your VA patients.

Navigating Insurance Requirements

Prior Authorization (PA) Checklist

An interactive PDF that highlights information typically required
for PAs.

Clinical Data

Ohtuvayre in the 2025 GOLD Report

Ohtuvayre is recommended in the 2025 GOLD report.

Ohtuvayre Overview for Healthcare Professionals

Provides a convenient resource for topline information on efficacy, safety, access, and patient support.

Warnings and Precautions:

Acute Episodes of Bronchospasm Ohtuvayre should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled, short-acting bronchodilator.

Paradoxical Bronchospasm As with other inhaled medicines, Ohtuvayre may produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with Ohtuvayre, it should be treated immediately with an inhaled, short-acting bronchodilator. Ohtuvayre should be discontinued immediately and alternative therapy should be instituted.

Psychiatric Events Including Suicidality Before initiating treatment with Ohtuvayre, healthcare providers should carefully weigh the risk and benefits of treatment with Ohtuvayre in patients with a history of depression and/or suicidal thoughts or behavior. Patients, their caregivers, and families should be advised of the need to be alert for the emergence or worsening of insomnia, anxiety, depression, suicidal thoughts, or other mood changes, and if such changes occur to contact their healthcare provider. Healthcare providers should carefully evaluate the risks and benefits of continuing treatment with Ohtuvayre if such events occur.

Treatment with Ohtuvayre is associated with an increase in psychiatric adverse reactions. Psychiatric events including suicide-related adverse reactions were reported in clinical studies in patients who received Ohtuvayre (1 suicide attempt and 1 suicide). Additionally, the most commonly reported psychiatric adverse reactions in the pooled 24-week safety population were insomnia (6 patients [0.6%] Ohtuvayre 3 mg; 2 patients [0.3%] placebo), and anxiety (2 patients [0.2%] Ohtuvayre 3 mg; 1 patient [0.2%] placebo). Depression-related reactions including depression, major depression, and adjustment disorder with depressed mood occurred in 4 patients [0.4%] receiving Ohtuvayre and no patients receiving placebo.

Adverse Reactions: The most common adverse reactions ≥1% in Ohtuvayre and greater than placebo in the pooled population were back pain 1.8%, hypertension 1.7%, urinary tract infection 1.3%, and diarrhea 1.0%.

These are not all of the possible risks associated with Ohtuvayre. Please see Full Prescribing Information for Ohtuvayre.

To report suspected adverse reactions, contact Verona Pharma, Inc. at
1-888-672-0371 or FDA at
1-800-FDA-1088 or
www.fda.gov/medwatch.